Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues, the use thereof and the preparation thereof.

Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, X, Y1, Y2, Y3, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNF?, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

Abstract: The present invention can provide a method for producing an aromatic nitrile in which a fixed-bed reactor including a plurality of reaction tubes is used to subject a gaseous mixture comprising an aromatic hydrocarbon, ammonia, and oxygen by contact catalytic reaction on a catalyst to thereby produce the corresponding aromatic nitrile, wherein the catalyst is composed of an oxide containing vanadium, chromium, and boron and one or more supports selected from among alumina, silica-alumina, zirconia, and titania. One of the reaction tubes is filled with the catalyst of one kind and examined as to where a hot spot lies therein. An inert substance is filled into that portion of each of the plurality of reaction tubes which corresponds at least to the hot spot, and the catalyst is filled into the remaining portions.

Abstract: Disclosed herein, inter alia, are novel reducing agents having the general formula and methods of use thereof.

Abstract: A compound of formula IVa includes two or three R1a to R4a groups which represent hydrogen, and the R1a to R4a groups not being hydrogen represent a group CH2—O—R6, CH2—O—C(?O)—R7, or —CH2—NR8R9, with R6 to R9 being a linear or branched alkyl group, alkoxy group, polyalkoxy group, or alkenyl group with at maximum 30 carbon atoms.

Abstract: Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ?-oxidation, such as ?-oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers.

Abstract: A fluorine-containing pyrimidine compound is provided represented by general formula (1), (2), (3), (4), (5), or (6) below. wherein, in the general formulae (1) to (6) above, R represents a hydrocarbon group having 1 to 12 carbon atoms; and X and Y each independently represent a hydrogen atom, a halogen atom, a hydrocarbon group having 1 to 10 carbon atoms, —CnF2n+1 (n is an integer of 1 to 10), a nitro group, a boronate group, —OA1, —SOmA1 (m is an integer of 0 to 3), —NA1A2, —COOA1, or —CONA1A2, and A1 and A2 each independently represent a hydrogen atom or a hydrocarbon group having 1 to 10 carbon atoms.

Abstract: The invention relates to carbon dioxide dioxaphosphetane compositions, including solid carbon dioxide dioxaphosphetane compositions. The invention includes compositions and methods for the capture, storage, and recycling of carbon, including methods of boric acid catalyzed reduction of carbonates in aqueous media and the use of phosphate solutions for capture and recycling of carbon.

Abstract: The present invention provides AHR agonists, compositions thereof, and methods of using the same.

Abstract: The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; R2 is a cyclic group substituted at the a and a? positions, wherein the substituent at the ?-position is a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl.

Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Abstract: This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPAR? or a ?-opioid receptor.

Abstract: The invention relates to clinical chemistry, in particular, to new biologically active compounds—amide derivatives of prostaglandin F2?. These compounds have low cytotoxicity and are capable of stimulating formation of endogenous nitrogen oxide in mammal cells. Synthesis of such compounds promotes expansion of nomenclature of biologically active derivatives of prostaglandin F2? capable of reducing intraocular pressure.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.

Abstract: Equipotent indolocarbazole-derived analogs of staurosporine identified herein are prepared through C—H borylation chemistry. Functionality resides at C2 and C10 of the indolocarbazole aromatic region. Introducing functionality in this previously inaccessible region does not abrogate kinase activity and is shown to change the selectivity profile.

Abstract: The present invention relates to novel dicarboxylic diesters as well as the use thereof as for inhibiting the methane production in ruminants.

Abstract: A new synthetic route to 2,2?,6,6?-tetraisopropyl-4,4?-diiodoazobenzene.

Abstract: A new synthetic route to a 2,2?-dimethyl-4,4?-diiodoazobenzene compound using homo-oxidative cross-coupling of an aryl diazonium salt using a Cu-catalyzed Sandmeyer-style reaction.